IGM Biosciences, Inc. Class Action Lawsuit - IGMS

Company
IGM Biosciences, Inc. (NASDAQ: IGMS)
Class Period
January 17, 2020 - January 17, 2025

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines

WhatsApp

Scan the QR code or click the button to join

Join on WhatsApp

Get Updates by Email

Required Field

Required Field

Required Field

No Spam, opt-out anytime, alert list is free

Allegations

The filed complaint alleges that IGM Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases." The press release quoted Mary Beth Harler, M.D., the Company's Chief Executive Officer, as stating that "[i]nterim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success[.]" Following this news, IGM's stock price fell over 66% on January 10, 2025.

Eligibility

In order to be eligible to join the IGMS class action lawsuit, you must have incurred a loss on shares of IGM Biosciences, Inc. purchased during the class definition listed above.

TOP